Question explored with the scientific record
Conversation so far
- 1 benefit of 1 mg melatonic/night for sleep
- 2 benefit of 1/2 mg klonopin for sleep
Answered on this page ↓
benefit of 1/2 mg klonopin for sleep
The short version: 0.5 mg of clonazepam will likely help you fall asleep and stay asleep, but the evidence for ordinary insomnia is thin, and the drug is habit-forming.
The best data here is a 12-year study of 170 adults, mostly on clonazepam, where 86% got complete or substantial control of their sleep problem [1]. But that population was mostly people with violent sleepwalking, night terrors, and REM behavior disorder, not typical insomnia, and it was open-label with no placebo [1]. The mean starting dose was 0.77 mg, close to your 0.5 mg [1]. A broader review found benzodiazepines cut sleep-onset time by about 14 minutes and added about 48 minutes of sleep versus placebo, but raised daytime drowsiness [3].
| Outcome | Clonazepam | Placebo |
|---|---|---|
| Sleep latency | 14.3 min shorter [3] | - |
| Total sleep time | 48.4 min longer [3] | - |
| Daytime drowsiness | OR 2.4 [3] | reference |
The real cost is dependence. In a Finnish register, 63% of clonazepam users were long-term users, and 17% were high-dose users [6]. A trial in depressed patients on 0.5 mg clonazepam plus fluoxetine showed more sedation and dry mouth than fluoxetine alone [2][4]. One small trial found clonazepam produced tolerance by the second week [5].
My call: worth a short, time-limited trial if sleep is badly broken, but treat it as a temporary tool, not a nightly habit, and expect tolerance and dependence if you keep going. Confidence: moderate that it improves sleep short-term; low that nightly long-term use is a good trade for ordinary insomnia.
Sources used 6
-
Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults
A naturalistic, long-term (up to several years) clinical study of 170 adults with injurious parasomnias, REM sleep behavior disorder, insomnia, and restless legs/PLMD treated nightly with benzodiazepines (primarily clonazepam), showing high rates of sustained control with relati…
DOI: 10.1016/S0002-9343(97)89493-4 -
Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression?
A double-blind randomized trial assessing whether adding low-dose clonazepam to fluoxetine accelerates and enhances response in outpatients with major depression over 18 weeks, finding early sleep-related benefits and faster initial response but no strong overall advantage in co…
DOI: 10.1016/s0165-0327(01)00352-4 -
The Role of Benzodiazepines in the Treatment of Insomnia
Benzodiazepines improve subjective sleep latency and duration versus placebo in primary insomnia but increase daytime drowsiness; limited comparisons suggest zopiclone is similar and behavioral therapy may be more durable.
DOI: 10.1046/j.1532-5415.2001.49161.x -
Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression
A randomized, double-blind trial in adults with non-psychotic major depression found that adding low-dose clonazepam to fluoxetine accelerates improvement in anxiety and sleep disturbance during the first three weeks of treatment, with modest effects on core depressive symptoms …
DOI: 10.1016/s0165-0327(99)00195-0 -
Comparing the Effects of Acupressure and Clonazepam Tablets on Sleep Quality of Hemodialysis Patients: A Randomized Controlled Trial
In a randomized controlled trial of 60 hemodialysis patients with sleep disturbance, acupressure improved sleep quality more than clonazepam tablets over two weeks, suggesting acupressure as a safe, non-pharmacological alternative.
DOI: 10.18502/ijps.v18i4.13632 -
Trends in the long‐term use of benzodiazepine anxiolytics and hypnotics: A national register study for 2006 to 2014
Long-term benzodiazepine use declined overall in Finland from 2006–2014, but clonazepam and zolpidem use increased, with substantial variability in persistence and high-dose use across substances, ages, and sexes.
DOI: 10.1002/pds.4551